Use of Blinatumomab for Relapse Therapy of B-Cell Precursor Acute Lymphoblastic Leukemia

被引：0
|
作者：
Pawinska-Wasikowska, K. [1 ,2 ]
Wyrobek, E. [2 ]
Klekawka, T. [1 ,2 ]
Luszawska-Kutrzeba, T. [2 ]
Garus, K. [2 ]
Pietrys, D. [2 ]
Zaniewska-Tekieli, A. [2 ]
Wieczorek, A. [1 ,2 ]
Balwierz, W. [1 ,2 ]
机构：
[1] Jagiellonian Univ, Coll Med, Dept Pediat Oncol & Hematol, Inst Pediat, Krakow, Poland
[2] Childrens Univ Hosp Krakow, Dept Pediat Oncol & Hematol, Krakow, Poland
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V177 SIOP1
引用
收藏
页码：S251 / S251
页数：1
相关论文
共 50 条
  • [31] The Usefulness of Blinatumomab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Review
    Watakabe, Mai
    Arakawa, Yuki
    Irikura, Tomoya
    Honda, Mamoru
    Mitani, Yuichi
    Oshima, Koichi
    Watanabe, Atsuko
    Mori, Makiko
    Fukuoka, Kohei
    Koh, Katsuyoshi
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [32] Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia
    Portell, Craig A.
    Wenzell, Candice M.
    Advani, Anjali S.
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2013, 5 : 5 - 11
  • [33] Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment
    Pourhassan, Hoda
    Agrawal, Vaibhav
    Pullarkat, Vinod
    Aldoss, Ibrahim
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [34] Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia
    Fuster, J. L.
    Bautista, F.
    Gonzalez, B.
    Fernandez, J. M.
    Rives, S.
    Dapena, J. L.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (09): : 1963 - 1966
  • [35] Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France
    Megane Caillon
    Benoit Brethon
    Chrissy van Beurden-Tan
    Romain Supiot
    Antoine Le Mezo
    Jean-Vannak Chauny
    Istvan Majer
    Arnaud Petit
    PharmacoEconomics - Open, 2023, 7 : 639 - 653
  • [36] Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France
    Caillon, Megane
    Brethon, Benoit
    van Beurden-Tan, Chrissy
    Supiot, Romain
    Le Mezo, Antoine
    Chauny, Jean-Vannak
    Majer, Istvan
    Petit, Arnaud
    PHARMACOECONOMICS-OPEN, 2023, 7 (4) : 639 - 653
  • [37] Advances in B-cell Precursor Acute Lymphoblastic Leukemia Genomics
    Schwab, Claire
    Harrison, Christine J.
    HEMASPHERE, 2018, 2 (04):
  • [38] Intraocular Invasion of B-Cell Precursor Acute Lymphoblastic Leukemia
    Torii, Daiki
    Nino, Nanako
    Masuda, Chika
    Nakatani, Naoko
    Tamura, Akihiro
    Yamamoto, Nobuyuki
    Ueda, Kaori
    Imai, Hisanori
    Nishimura, Noriyuki
    Nozu, Kandai
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [39] CD33+ B-CELL PRECURSOR ACUTE LYMPHOBLASTIC-LEUKEMIA IN CHILDREN - A DISTINCT SUBGROUP OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC-LEUKEMIA
    HARA, J
    HOSOI, G
    OKAMURA, T
    OSUGI, Y
    ISHIHARA, S
    YUMURAYAGI, K
    KAWAHA, K
    TAWA, A
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 1995, 61 (02) : 77 - 84
  • [40] A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Horibe, Keizo
    Morris, Joan D.
    Tuglus, Catherine A.
    Dos Santos, Cedric
    Kalabus, James
    Anderson, Abraham
    Goto, Hiroaki
    Ogawa, Chitose
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 112 (02) : 223 - 233
12345